This methodology has been effective in uncovering optimal drug targets in various contexts, including previously established targets for breast cancer (e.g., SRC, MTOR) (17) and spinal cord injury (e.g., TNF, FOS, IL6) (18). This evidence concerns the gene SRC and breast cancer.